Project Details
Description
The EU is facing security challenges as CBRN threats especially of intended origin. It is thus critical that Europe develops
relevant capabilities through medical countermeasures for which today very few are approved for use and available to
European armed forces. The RESILIENCE project aims to build a European collaborative ecosystem against current
or future CBRN threats, including research institutes, universities, RTOs, hospitals, industries, mid-caps and SMEs.
It will be based on a multiannual action plan of research and development activities established in consultation with
relevant authorities leading to effective and efficient medical countermeasures. Such countermeasures would then be
industrialized, transferred and used by the armed forces for improving EU preparedness for CBRN military crises and
fostering EU sovereignty.
The main concept of the RESILIENCE multiannual action plan is based on a time-related deployment of armed forces in
a theatre of operations where multiple health conditions requiring MCMs may occur. The action plan is organized around
three main pillars of MCMs: Diagnosis, Prevention/Prophylaxis and Treatment which will respond to chemical (nerve
agents, yperite, ricin and abrin), biological (pox viruses, viral hemorrhagic fevers, Y. pestis, B. anthracis, B. pseudo
mallei and Botulinum toxins) and radiological and nuclear threats. Innovative diagnostic tools (e.g., on-field tools), novel
vaccines (e.g., antibody-based, vaccine with high cross orthopox protection efficacy) and more efficient treatments (e.g.,
decorporating agents, reactivators of cholinesterases, phage therapy) will be developed.
By gathering a critical mass of European players who will collaborate to provide European armed forces with novel
efficient MCMs, RESILIENCE will contribute to strengthening the autonomy of the European sovereignty, to developing
EU autonomous industrial segments and to maintaining the operational capacity of soldiers in the field.
relevant capabilities through medical countermeasures for which today very few are approved for use and available to
European armed forces. The RESILIENCE project aims to build a European collaborative ecosystem against current
or future CBRN threats, including research institutes, universities, RTOs, hospitals, industries, mid-caps and SMEs.
It will be based on a multiannual action plan of research and development activities established in consultation with
relevant authorities leading to effective and efficient medical countermeasures. Such countermeasures would then be
industrialized, transferred and used by the armed forces for improving EU preparedness for CBRN military crises and
fostering EU sovereignty.
The main concept of the RESILIENCE multiannual action plan is based on a time-related deployment of armed forces in
a theatre of operations where multiple health conditions requiring MCMs may occur. The action plan is organized around
three main pillars of MCMs: Diagnosis, Prevention/Prophylaxis and Treatment which will respond to chemical (nerve
agents, yperite, ricin and abrin), biological (pox viruses, viral hemorrhagic fevers, Y. pestis, B. anthracis, B. pseudo
mallei and Botulinum toxins) and radiological and nuclear threats. Innovative diagnostic tools (e.g., on-field tools), novel
vaccines (e.g., antibody-based, vaccine with high cross orthopox protection efficacy) and more efficient treatments (e.g.,
decorporating agents, reactivators of cholinesterases, phage therapy) will be developed.
By gathering a critical mass of European players who will collaborate to provide European armed forces with novel
efficient MCMs, RESILIENCE will contribute to strengthening the autonomy of the European sovereignty, to developing
EU autonomous industrial segments and to maintaining the operational capacity of soldiers in the field.
| Acronym | RESILIENCE |
|---|---|
| Status | Active |
| Effective start/end date | 1/01/24 → 31/12/27 |
Collaborative partners
- Commissariat à l'énergie atomique et aux énergies alternatives (CEA) (Coordinator) (lead)